This segment focuses on the research, development, and commercialization of innovative therapies for various cancers. Junshi Biosciences has a robust pipeline of oncology drug candidates, including the anti-PD-1 monoclonal antibody, toripalimab (TUOYIR), approved for multiple indications. Research and development activities include clinical trials across different tumor types, exploring combination therapies, and developing novel targeted therapies. The company utilizes advanced technologies such as monoclonal antibody engineering and immunotherapy approaches. The patient impact is significant, offering new treatment options and improving survival rates for cancer patients. Junshi Biosciences aims to be a leader in the oncology market in China and globally, with strategic partnerships to expand market access. Future opportunities include expanding indications for existing drugs and developing new cancer therapies. Regulatory and clinical aspects involve rigorous clinical trials and seeking approvals from regulatory bodies like the NMPA and FDA. Partnerships with companies like Merck & Co., Inc. and Coherus Biosciences, Inc. are crucial for co-development and commercialization efforts.

This segment is dedicated to developing therapies for autoimmune and metabolic diseases. Junshi Biosciences is developing UBP1211, a biosimilar of Humira (adalimumab), for rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis. The company also has programs for anti-PCSK9 monoclonal antibodies (JS002) for hyperlipidemia and anti-BLyS monoclonal antibodies (UBP1213). Research and development activities include preclinical and clinical studies to evaluate the safety and efficacy of these drug candidates. The company utilizes technologies such as monoclonal antibody development and biosimilar manufacturing. The patient impact is focused on providing effective treatments for chronic conditions and improving the quality of life for patients. Junshi Biosciences aims to capture a significant share of the market for autoimmune and metabolic disease treatments in China and globally. Future opportunities include expanding the pipeline with new drug candidates and biosimilars. Regulatory and clinical aspects involve conducting clinical trials and obtaining regulatory approvals. Partnerships may be formed to facilitate commercialization and market access.

This segment focuses on the development of therapies for infectious diseases, including potential treatments for COVID-19. Junshi Biosciences has a collaboration with Eli Lilly and Company to co-develop therapeutic antibodies for the prevention and treatment of COVID-19. Research and development activities include antibody discovery, preclinical studies, and clinical trials. The company utilizes technologies such as antibody engineering and antiviral drug development. The patient impact is focused on addressing unmet medical needs and providing effective treatments for infectious diseases. Junshi Biosciences aims to contribute to global efforts in combating infectious diseases. Future opportunities include expanding the pipeline with new drug candidates and exploring partnerships for commercialization. Regulatory and clinical aspects involve conducting clinical trials and obtaining regulatory approvals. Partnerships with companies like Eli Lilly are crucial for co-development and commercialization.